Analogues

Sclerovain , Ethoxysclerol .

pharmachologic effect

The drug has a venosclerosing effect, has surface- ‑active properties.

Indications for use

Treatment of uncomplicated, moderately severe varicose veins of the lower extremities by compression sclerotherapy. Treatment of telangiectasias.

Dosage and administration

Before conducting a course of venous sclerosing therapy, it is necessary to conduct a trial administration of the drug to identify possible individual intolerance. The drug is injected into the distal areas, freed from blood, varicose veins, followed by immediate and prolonged elastic compression. The choice of drug concentration depends on the diameter of the varicose vein to be treated. 3% of the drug is ‑intended for obliteration of large diameter varicose veins (1 cm or more), 1% is used to treat superficial varicose veins up to 1 cm in diameter, 0.5% and 0.2% of the ‑drug is used for injection sclerotherapy of intradermal varicose veins veins and telangiectasias. In the presence of an extensive widespread varicose process, injections of ‑rra are repeated 2-10 times at intervals of 3-5 days.

Side effects

During the administration of the drug, especially during the first treatment session, dizziness, headache, nausea and increased sweating may occur. With the introduction of the drug, a burning sensation and slight soreness at the injection site are noted. If the drug gets under the skin, hyperpigmentation, infiltration and skin necrosis may develop.

Allergic reactions rarely occur. In case of accidental intravenous injection – obliteration of the afferent vessel, embolism; with paravenous – the development of soft tissue necrosis.

Contraindications

Hypersensitivity to the drug; BA; severe liver and kidney disease; acute thrombosis and thrombophlebitis; soft tissue infection; infectious diseases; obliterating peripheral arteriosclerosis; diabetic angiopathy; pregnancy and lactation; after treatment for alcoholism; obesity; taking oral contraceptives; sedentary lifestyle; varicose veins, as a result of a tumor of the abdominal cavity and small pelvis; heart defects requiring surgical intervention; extensive and pronounced varicose veins with valve insufficiency; phlebosclerosis; fever; toxic hyperthyroidism; oncological diseases; acute infections; tuberculosis; sepsis; violation of the cellular composition of the blood; acute respiratory or skin diseases; common diseases requiring bed rest, heart disease with symptoms of decompensation.

Overdose

There is no data. If the dosage is exceeded in small vessels, necrosis may develop.